---
title: Imaging predicts impulse control risk
nct_id: NCT07213219
phase: NA
status: RECRUITING
sponsor: University Hospital, Clermont-Ferrand
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT07213219"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07213219"
last_fetched: "2026-07-08T14:01:19.331Z"
source: "Parkinson's Pathways (curated)"
---
# Imaging predicts impulse control risk

**Goal (in five words):** Imaging predicts impulse control risk

**Official Title:** Exploration of the Reward System in Parkinson's Patients With Paradoxical Sleep Behavior Disorders: a Multimodal Imaging Study

**Trial ID:** [NCT07213219](https://clinicaltrials.gov/study/NCT07213219)

## Key Facts

- **Phase:** NA
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** University Hospital, Clermont-Ferrand
- **Target Enrollment:** 44 participants
- **Start Date:** 2026-05-07
- **Completion Date:** 2028-01-01
- **Conditions:** Parkinson's Disease (PD)
- **Interventions:** PET-MRI (Positron Emission Tomography - Magnetic Resonance Imaging).
- **Intervention Types:** OTHER

## Summary For Families

Goal: Find out whether people with Parkinson's who act out their dreams, a condition called rapid eye movement sleep behavior disorder, have different levels of D2 dopamine receptors in the brain's reward areas, which might help explain why some develop impulse control problems on dopamine treatments. Approach: Participants will have a combined positron emission tomography and magnetic resonance imaging brain scan that measures how many D2 dopamine receptors are available in reward-related regions, and researchers will compare those with and without the sleep behavior disorder. Eligibility: Adults 45 to 80 with idiopathic Parkinson's for at least 3 years who have been on dopaminergic treatment including levodopa for at least one year; people with existing impulse control problems, severe depression, major cognitive or motor problems, or contraindications to PET-MRI are excluded.

## What This Actually Involves

**Placebo** _(From the protocol)_: There is no placebo group. Everyone receives an active treatment; the study compares one treatment against another.

**Visits** _(Ask the coordinator)_: Ask the coordinator how many in-person visits the study involves, how long each one takes, and over what total period.

**Procedures** _(From the protocol)_:
- PET scan (Minimally invasive)
  > "PET-MRI (Positron Emission Tomography - Magnetic Resonance Imaging)."
- MRI scan (Non-invasive)
  > "PET-MRI (Positron Emission Tomography - Magnetic Resonance Imaging)."

**Washout** _(Ask the coordinator)_: Ask the coordinator whether you would need to stop or pause any of your current medications before or during the study (a washout period), and for how long.

**Travel & reimbursement** _(Ask the coordinator)_: Ask the coordinator whether travel, parking, or your time is reimbursed or compensated, and what is covered.

_Fields marked “From the protocol” come from the trial's registry record or quoted protocol text. Fields marked “Ask the coordinator” are not reliably available and should be confirmed directly._

## Eligibility

- **Minimum age:** 45 Years
- **Maximum age:** 80 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* Patients aged 45 to 80 years
* Patients diagnosed with idiopathic Parkinson's disease (PD) according to the Movement Disorder Society criteria
* Duration of Parkinson's disease progression ≥ 3 years
* Patients receiving chronic dopaminergic treatment including levodopa for at least one year to avoid tolerance issues during acute levodopa administration
* Ability to cooperate and understand, allowing strict compliance with the conditions set forth in the protocol
* Patients affiliated with or beneficiaries of a social security system
* Volunteer patients capable of providing informed consent to participate in the research

Exclusion Criteria:

* Patients suffering from neurological disorders other than idiopathic Parkinson's disease (PD)
* Patients with severe depression (Beck Depression Inventory \\\[20\] (BDI) score \> 30), apathy (Starkstein scale \\\[21\] score ≥ 14), cognitive impairment (Montreal Cognitive Assessment \\\[MoCA\] \\\[22\] score \< 25).
* Patients with impulse control disorders, defined by either of the following:

  * A score of ≥ 6 on the "Pathological Gambling" item, ≥ 8 on the "Compulsive Buying" item, ≥ 8 on the "Sexual Behavior" item, or ≥ 7 on the "Eating Behavior" item, and more than one positive response (score \> 0) on the corresponding QUIP-RS items for Gambling, Compulsive Buying, Sexual Behavior, and Eating Behavior.
  * A total QUIP-RS score ≥ 10.
* Patients with severe motor symptoms: patients with an MDS-UPDRS III score \> 45 will be excluded to avoid severe discomfort or interfering tremor (tremor item ≥ 3 in any body part) in the OFF state during PET-MRI acquisition. Patients with severe dyskinesias will also be excluded due to technical issues related to movement
* Patients under guardianship, curatorship, deprived of liberty, or under legal protection
* Pregnant or breastfeeding women
* Patients with contraindications to PET-MRI (e.g., those with pacemakers or insulin pumps, metallic prostheses or intracerebral clips, claustrophobia, neurosensorial stimulators or implantable defibrillators, cochlear implants, ferromagnetic ocular or cerebral foreign bodies near nervous structures, uncooperative or agitated patients, neurosurgical ventriculoperitoneal shunts, dental appliances)
* Refusal to participate
```

## Locations (3)

- CHU Clermont-Ferrand, Clermont-Ferrand,, Clermont-Ferrand, France _(45.7797, 3.0868)_
  - Lise LACLAUTRE, (CONTACT), +33473754963, promo_interne_drci@chu-clermontferrand.fr
  - Charlotte BEAL, (PRINCIPAL_INVESTIGATOR)
- CH Le Puy en Velay, Le Puy-en-Velay, France _(45.0437, 3.8852)_
  - Jeremy DASSA, (PRINCIPAL_INVESTIGATOR)
- CHRU Lyon, Lyon, France _(45.7491, 4.8479)_
  - Stéphane THOBOIS, (PRINCIPAL_INVESTIGATOR)

## Central Contacts

- Lise LACLAUTRE, (CONTACT), +334.73.754.963, promo_interne_drci@chu-clermontferrand.fr

---

*Canonical: https://parkinsonspathways.com/trial/NCT07213219*  
*HTML version: https://parkinsonspathways.com/trial/NCT07213219*  
*Source data: https://clinicaltrials.gov/study/NCT07213219*